Avacta Life Sciences Limited
  • About
  • Therapeutics
    • Therapeutics
    • preCISIONTM
    • Affimer®
    • Pipeline
    • Partners
    • Clinical trials
    • Team
    • News
  • Diagnostics
  • Investors
  • News
  • Careers
  • Contact
  • About
    • About Avacta
    • Group Team
    • Scientific Resources
    • Intellectual Property
    • Virtual tour
  • Therapeutics
    • Therapeutics
    • preCISIONTM
    • Affimer®
    • Pipeline
    • Partners
    • Clinical trials
    • Team
    • News
  • Diagnostics
    • Diagnostics
    • Our Brands
    • Affimer®
    • Team
    • News
  • Investors
    • Investors
    • CEO Welcome
    • Key info
    • Corporate Governance
    • Resources
    • Share price
    • RNS News
    • Research
  • News
  • Careers
    • Job vacancies
    • About Avacta
    • Benefits of working at Avacta
  • Contact
  • About
    • About Avacta
    • Group Team
    • Scientific Resources
    • Intellectual Property
    • Virtual tour
  • Therapeutics
    • Therapeutics
    • preCISIONTM
    • Affimer®
    • Pipeline
    • Partners
    • Clinical trials
    • Team
    • News
  • Diagnostics
    • Diagnostics
    • Our Brands
    • Affimer®
    • Team
    • News
  • Investors
    • Investors
    • CEO Welcome
    • Key info
    • Corporate Governance
    • Resources
    • Share price
    • RNS News
    • Research
  • News
  • Careers
    • Job vacancies
    • About Avacta
    • Benefits of working at Avacta
  • Contact
Home News Therapeutics Page 2
filter by: view all | Blogs | Diagnostics | Investors | Therapeutics

Therapeutics

23 Feb 2023

Avacta Therapeutics Division Science Day

Investors | Therapeutics
17 Jan 2023

Avacta Announces Successful Completion of Fourth Dose Escalation in AVA6000 Phase 1 Clinical Study

Investors | Therapeutics
19 Dec 2022

Avacta to Host Therapeutics Division Science Day on 23rd February 2023

Investors | Therapeutics
31 Oct 2022

Avacta to Present at Virtual Theranostics FAP Summit

Investors | Therapeutics
05 Sep 2022

AVA6000 receives Orphan Drug Designation from the US Food and Drug Administration

Investors | Therapeutics
01 Sep 2022

Phase I clinical study of AVA6000 to advance to the fourth cohort

Investors | Therapeutics
21 Jul 2022

AffyXell Successfully Completes Funding Round

Investors | Therapeutics
30 Jun 2022

LG Chem renews license triggering payment to Avacta

Investors | Therapeutics
29 Jun 2022

Avacta announces second dose escalation in the Phase I clinical study of AVA6000 Pro-doxorubicin

Investors | Therapeutics
16 May 2022

AffyXell expands its strategic partnership with GenScript ProBio

Investors | Therapeutics

Posts navigation

Older posts
Newer posts
Avacta Life Sciences Limited
  • Terms of Use
  • Terms & Conditions
  • Privacy Policy
  • Intellectual Property
  • Returns & cancellations policy
  • Corporate Responsibility
  • Contact Us

Avacta Diagnostics

Unit 20, Ash Way
Thorp Arch Estate
Wetherby
LS23 7FA
+44 (0)1904 21 7070

virtual tour
email

Avacta Therapeutics

Scale Space,  White City
Imperial College Campus
58 Wood Lane
London
W12 7RZ

+44 (0)20 3871 9700

Investor Enquiries

Consilium
Strategic Communications
85 Gresham Street
London
EC2V 7NQ

Email

Twitter | Linkedin

©2023 Avacta Life Sciences Limited. Registered company no. 06605196.